Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 23 Nov 2018 |
| Oral semaglutide demonstrates greater reductions in both HbA1c and body weight compared to Victoza® in Japanese people with type 2 diabetes | 22 Nov 2018 |
| Novo Nordisk A/S - Share repurchase programme | 15 Nov 2018 |
| Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2018 | 6 Nov 2018 |
| Novo Nordisk A/S purchases B shares worth DKK 1,262 million from Novo Holdings A/S under the 2018 share repurchase programme | 5 Nov 2018 |